Estimates vary. In 2013, New York Times suggested that up to 30% of otherwise healthy women between the ages of 20 and 60 are affected. Sprout Pharmaceutical and Palatin Technologies, two companies actively developing medications to treat HSDD, report 43% and 12% respectively. Even at the lower end of the range, it is likely that well over ten million women in the USA alone experience HSDD. Both post- and pre-menopausal women can be affected.